Zydus Lifesciences Ltd.
BSE: 532321 | NSE: ZYDUSLIFE
Mid Cap | Pharmaceuticals & Drugs
942.55
3.35 (0.36%) Zydus Lifesciences informs about press release
Date: 06-11-2025Zydus Lifesciences has informed that it enclosed a copy of press release dated November 6, 2025, titled ‘Zydus receives USFDA Orphan Drug Designation (ODD) for Desidustat for the treatment of betathalassemia’.
The above information is a part of company’s filings submitted to BSE.